Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy

AIM: Combination therapy with gemcitabine and nanoparticle albumin-bound paclitaxel (nab-paclitaxel), known as GnP therapy, significantly prolongs the survival of pancreatic cancer patients compared with gemcitabine monotherapy. However, it may cause severe neutropenia, requiring discontinuation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Genta, Kawakami, Kazuyoshi, Aoyama, Takeshi, Yokokawa, Takashi, Nakamura, Masashi, Ozaka, Masato, Sasahira, Naoki, Hashiguchi, Masayuki, Kizaki, Hayato, Hama, Toshihiro, Hori, Satoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279319/
https://www.ncbi.nlm.nih.gov/pubmed/34260659
http://dx.doi.org/10.1371/journal.pone.0254726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279319/
https://www.ncbi.nlm.nih.gov/pubmed/34260659
http://dx.doi.org/10.1371/journal.pone.0254726

Ejemplares similares